Growth hormone secretagogues (GHS) are compounds that push your own pituitary to release more somatotropin. That is the main difference from injecting recombinant growth hormone: you do not add a finished hormone from outside, you prompt the gland to work harder. The signal runs through the same receptors the body uses every day, so the output stays pulsatile rather than a flat background level.

Inside the category there are two different mechanisms, and it helps not to mix them up.

Two receptors, two families

GHRH analogs

GHRH is a hypothalamic hormone that tells the pituitary to make and release somatotropin. The analogs copy that instruction. This group includes sermorelin and tesamorelin, plus the best known one in research circles, CJC-1295. That molecule comes in two forms. Without DAC (also called Mod GRF 1-29) it acts briefly, a matter of minutes. With DAC, meaning an added complex that binds to blood albumin, the half-life stretches into days and the hormone level holds longer. There is more on the DAC version in our CJC-1295 DAC reference.

Ghrelin mimetics

The second branch works through the GHS-R receptor, the one ghrelin (the hunger hormone) binds to. These compounds do two things: they prompt somatotropin release and they quiet somatostatin, the body's own braking signal. The group includes GHRP-6, GHRP-2, hexarelin, the more selective ipamorelin, and the oral non-peptide MK-677 (ibutamoren). GHRP-6 raises appetite noticeably because it is close to ghrelin; ipamorelin barely does this and touches cortisol and prolactin far less. We covered the basics of GHRP-6 separately.

Why they get combined

Because a GHRH analog and a ghrelin mimetic act through different receptors, together they produce a larger hormone release than either alone. The classic research pairing is CJC-1295 with ipamorelin or some GHRP. One primes the pituitary, the other lifts the brake and adds a push. Even that combination has a ceiling, though: somatostatin and the gland's own capacity will not let the level climb without limit, and this is where secretagogues differ fundamentally from injecting the hormone directly.

Somatotropin or a secretagogue

Recombinant somatotropin (somatropin) is the hormone itself. It works as replacement, bypassing the natural feedback loop, which is why it can push levels well above physiological. Secretagogues leave that loop in place. The pituitary still listens to somatostatin, so the body keeps part of its self-regulation. From there the mechanism is shared: somatotropin acts on the liver, the liver makes IGF-1, and that factor mediates most of the anabolic signaling.

What the data actually shows

This calls for honesty. The most human data exists for MK-677: it reliably raises somatotropin and IGF-1 and has been studied in clinical work, including in older adults and in conditions with muscle loss. For CJC-1295, ipamorelin and GHRP-6, most of the material is preclinical work and small early studies; long controlled human trials are missing. Tesamorelin is a separate exception, approved for one specific medical indication, but that does not turn the whole category into medicines. Put plainly: there is a signal, but the evidence base is uneven and in places thin.

Side effects and limits

The ones mentioned most often:

  • fluid retention, puffiness, sometimes numbness or tingling in the fingers;
  • increased appetite, especially on GHRP-6 and MK-677;
  • effects on insulin sensitivity and blood glucose, described in most detail for MK-677;
  • with the less selective GHRPs, a possible rise in prolactin and cortisol.

These are research-use compounds, not a ready therapy. This text is educational, is not medical advice, and does not describe treating or preventing any condition. Longeva supplies growth hormone secretagogues for laboratory and research work; if a specific molecule interests you, start with its reference page, and leave any decision about use to a qualified professional.

Research compounds from this review in our catalog: CJC-1295 with DAC, GHRP-6.